Cannabinoids Market Report 2026

The cannabinoids market size has grown exponentially in recent years. It will grow from $47.03 billion in 2025 to $56.75 billion in 2026 at a compound annual growth rate (CAGR) of 20.7%. The growth in the historic period can be attributed to increasing legalization of medical cannabis programs, rising prevalence of chronic pain and cancer treatments, growing acceptance of alternative therapies, expansion of hospital pharmacy distribution, development of standardized cannabinoid formulations.

The cannabinoids market size is expected to see exponential growth in the next few years. It will grow to $120.57 billion in 2030 at a compound annual growth rate (CAGR) of 20.7%. The growth in the forecast period can be attributed to expansion of clinical research on cannabinoids, increasing demand for pharmaceutical-grade cannabinoid products, rising regulatory clarity across regions, growth of cannabinoid-based personalized medicine, increasing investments in cannabinoid manufacturing infrastructure. Major trends in the forecast period include increasing medical adoption of cannabinoid-based therapies, rising demand for cbd-dominant products, growing use of cannabinoids in chronic disease management, expansion of regulated cannabinoid supply chains, enhanced focus on product standardization and purity.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the cannabinoid market. Chronic diseases are defined as illnesses that persist for a year or longer and require continuous medical care. The efficacy of cannabinoids, including smoked marijuana, oromucosal extracts of cannabis-based medications, nabilone, dronabinol, and a novel THC analogue, in managing chronic noncancer pain was evaluated in a systematic review of randomized controlled trials. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported that in 2023, around 194 million U.S. adults, or 76.4%, had at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Consequently, the growing prevalence of chronic diseases is fueling the expansion of the cannabinoid market.

Major companies in the cannabinoids market are concentrating on developing innovative solutions, such as fast-acting cannabinoids, to improve the efficacy and speed of therapeutic effects. Fast-acting cannabinoids are cannabinoid formulations that deliver quicker therapeutic benefits after consumption compared to traditional methods. For example, in August 2024, Rare Cannabinoid, a US-based health and wellness company, introduced Fast-Acting Nano THC + CBC Mood Mints, expanding its popular mood product line with a novel delivery approach. These mints are designed to provide rapid effects, enabling users to experience the benefits of delta-9-THC and cannabichromene (CBC) within 15 to 30 minutes, compared to the usual 30 to 90 minutes for conventional edibles. By leveraging advanced nanotechnology, the mints offer flexible dosing options suitable for both microdosing and personalized needs.

In April 2023, MediPharm Labs Corp., a Canada-based producer of medical and recreational cannabis products, acquired VIVO Cannabis Inc., for an undisclosed sum. Through this acquisition, MediPharm Labs aims to expand its production capacity, enhance its market presence in the Canadian cannabis sector, diversify its product portfolio, and improve operational efficiencies across its cultivation and extraction facilities. VIVO Cannabis Inc., a Canada-based licensed cannabis producer, specializes in creating high-quality cannabis products for both medical and adult-use markets.

Major companies operating in the cannabinoids market are The Supreme Cannabis Company Inc., Elixinol Global Limited, GW Pharmaceuticals PLC, Tilray Inc., Aurora Cannabis Inc., Curaleaf Holdings Inc., Green Thumb Industries, Verano Holdings, Trulieve Cannabis Corp., Cresco Labs Inc., Cronos Group, TerrAscend Corp., Canopy Growth Corp., Sundial Growers Inc., Decibel Cannabis Company, Auxly Cannabis Group, Red White & Bloom Brands, BZAM Ltd, Delta 9 Cannabis Inc., Jazz Pharmaceuticals PLC, Aphria Inc., Organigram Inc., MediPharm Labs Corp., The Valens GroWorks Inc.

North America was the largest region in the cannabinoids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabinoids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cannabinoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cannabinoids market by increasing costs of imported extraction equipment, pharmaceutical-grade processing systems, laboratory testing instruments, and packaging materials. Medical and pharmaceutical segments in North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces cost pressures in export-oriented cannabinoid processing. These tariffs are raising production and compliance costs. At the same time, they are encouraging domestic cultivation, localized extraction facilities, and regional supply chain development for regulated cannabinoid products.

The cannabinoids market research report is one of a series of new reports that provides cannabinoids market statistics, including cannabinoids industry global market size, regional shares, competitors with a cannabinoids market share, detailed cannabinoids market segments, market trends and opportunities, and any further data you may need to thrive in the cannabinoids industry. This cannabinoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cannabinoids are specific chemicals found in marijuana that produce effects similar to drugs on the immune and central nervous systems. They are used to manage the side effects or symptoms of chronic conditions, such as those experienced during cancer treatment.

The primary product types of cannabinoids include cannabidiol, tetrahydrocannabinol, cannabinol, and other variants. Cannabidiol is used to treat patients experiencing seizures, anxiety, insomnia, chronic pain, and tobacco dependence. It is a chemical derived from the cannabis sativa plant or hemp. The distribution channels for cannabinoids include hospital pharmacies, retail pharmacies, and online stores. Their applications span medical use, recreational purposes, and industrial hemp.

The cannabinoids market consists of sales of cannabidiolic acid, flowers/buds and concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.